Skip to content

Epilepsy Health Center

Epilepsy Drugs Get Suicide Risk Warning

FDA Orders a Warning for Antiepileptic Drugs About Increased Risk of Suicidal Thoughts and Behaviors
Font Size
A
A
A
By
WebMD Health News
Reviewed by Louise Chang, MD

Dec. 16, 2008 -- The FDA today announced that it will require makers of epilepsy drugs to add a warning about increased risk of suicidal thoughts and behaviors to the products' prescribing information or labeling.

The warning -- which won't be a "black box" warning -- applies to all antiepileptic medications, including those used to treat psychiatric disorders, migraines, and other conditions, as well as epilepsy.

Here is a list of the medications required to add the warning:

  • Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)
  • Clonazepam (marketed as Klonopin)
  • Clorazepate (marketed as Tranxene)
  • Divalproex sodium (marketed as Depakote, Depakote ER, Depakene)
  • Ethosuximide (marketed as Zarontin)
  • Ethotoin (marketed as Peganone)
  • Felbamate (marketed as Felbatol)
  • Gabapentin (marketed as Neurontin)
  • Lamotrigine (marketed as Lamictal)
  • Lacosamide (marketed as Vimpat)
  • Levetiracetam (marketed as Keppra)
  • Mephenytoin (marketed as Mesantoin)
  • Methosuximide (marketed as Celontin)
  • Oxcarbazepine (marketed as Trileptal)
  • Phenytoin (marketed as Dilantin Suspension)
  • Pregabalin (marketed as Lyrica)
  • Primidone (marketed as Mysoline)
  • Tiagabine (marketed as Gabitril)
  • Topiramate (marketed as Topamax)
  • Trimethadione (marketed as Tridione)
  • Zonisamide (marketed as Zonegran)

Some of those drugs are also sold generically.

Monitor Patients

"Patients being treated with antiepileptic drugs for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior," Russell Katz, MD, says in an FDA news release.

Katz, who directs the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, says that "patients who are currently taking an antiepileptic medicine should not make any treatment changes without talking to their health care professional."

The FDA also issued a public health alert about the risk and asked health care professionals to notify patients, their families, and caregivers about the risk, so that patients may be closely observed. And the FDA has ordered epilepsy drugmakers to create a risk evaluation and management strategy, including a medication guide for patients, addressing the risk.

Epilepsy Drugs and the FDA

Today's FDA actions are based on the agency's review of 199 clinical trials of 11 epilepsy drugs. The review, which the FDA released in January, showed that patients taking those drugs had almost twice the risk of suicidal behavior or thoughts than patients taking a placebo.

Today on WebMD

human head and brain waves
Causes, symptoms, and treatments.
Grand mal seizure
How is each one different?
 
marijuana plant
CBD, a plant chemical, may cut down seizures.
prescription bottle
Which medication is right for you?
 
Seizures Driving
Article
Questions for Doctor Epilepsy
Article
 
Pills spilling from bottle in front of clock
Article
Graces Magic Diet
VIDEO
 
Pets Improve Your Health
SLIDESHOW
Caring Child Epilepsy
Article
 
Making Home Safe
Article
Epilepsy Surgery Cure
VIDEO